Genovis (OM:GENO) Stock Faces Margin Compression As Net Profitability Undercuts Bullish Growth Narratives

Genovis AB (publ.) (OM:GENO) has posted its Q2 2026 numbers with revenue of SEK38.0 million and basic EPS of SEK0.02, alongside trailing 12 month totals of SEK142.1 million in revenue and SEK0.31 in EPS that frame the latest quarter within a broader earnings profile. Over recent periods the company has seen revenue range from SEK27.7 million to SEK40.5 million per quarter while basic EPS has moved between SEK0.02 and SEK0.12, giving investors a clear view of how the latest print fits into the recent run rate before they focus on what it might mean for future growth. With trailing net margins lower than a year ago, the Q2 result puts the spotlight on how Genovis is balancing expansion with margin resilience.

See our full analysis for Genovis AB (publ.).

With the latest figures on the table, the next step is to see how these results line up against the prevailing narratives around Genovis, highlighting where the story is supported by the data and where expectations might need to adjust.

Curious how numbers become stories that shape markets? Explore Community Narratives

Margins Compressed as Net Margin Slips to 14.4%

• On a trailing 12 month basis Genovis AB (publ.) generated Net Income (excl. extra items) of SEK20.5 million on revenue of SEK142.1 million, which corresponds to a net margin of about 14.4% compared with 21.9% a year earlier as referenced in the analysis.
• Critics highlight that the bearish concern around profitability finds support in this margin picture,
  • Trailing 12 month Basic EPS of SEK0.31 sits below the SEK0.41 level recorded a year earlier in the data, which lines up with the comment that earnings have declined at an annualised rate of 1.9% over five years.
  • The move in net margin from 21.9% to 14.4% gives bears a concrete data point when they focus on how much earnings strength backs the current valuation.

Revenue Growth Expectations vs Recent Profit Trend

• The data flags revenue growth forecasts of about 20.1% per year and earnings growth of roughly 47% per year. The latest Q2 2026 Net Income (excl. extra items) of SEK1.3 million compares with SEK4.3 million in Q1 2026 and SEK6.9 million in Q4 2025, showing a softer recent profit run rate against those growth expectations.
• What is surprising is how the bullish growth story sits alongside that softer profit trend,
  • Supporters of the bullish view point to the SEK142.1 million of trailing 12 month revenue as a base for those forecast growth rates. However, the trailing 12 month Net Income of SEK20.5 million is lower than the SEK27.0 million level in the prior year period referenced in the data.
  • This mix of strong forecasted growth with trailing earnings that have eased slightly over five years means readers need to weigh whether the growth outlook or the recent profit trend matters more for their own view.

Premium P/E and DCF Fair Value Gap

• Genovis trades on a trailing P/E of 64.6x compared with 45.2x for peers and 36.6x for the Global Life Sciences industry. A DCF fair value of SEK28.15 sits above the current share price of SEK20.05 in the data, leaving the stock about 28.8% below that modelled value.
• Consensus style thinking in the analysis frames this as a valuation trade off rather than a simple bargain,
  • The higher P/E than both peers and industry suggests the market is already assigning Genovis a premium, even though the share price is below the DCF fair value of SEK28.15.
  • At the same time the slip in trailing margins to 14.4% provides a counterpoint to that premium, so readers can compare the higher multiple with the DCF fair value gap when judging whether the current SEK20.05 price aligns with their own expectations.

📊 Read the what the Community is saying about Genovis AB (publ.).

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Genovis AB (publ.)'s growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If the mixed tone on Genovis AB (publ.) still leaves you on the fence, act now by reviewing the full data, weighing both concerns and potential upsides, and grounding your own judgment in the 2 key rewards and 1 important warning sign.

See What Else Is Out There

Genovis AB (publ.) is carrying a premium P/E while net margins and trailing earnings sit below prior levels, leaving some investors questioning the balance between price and profitability.

If that mix of softer profitability and a higher multiple worries you, compare Genovis with companies screened for quality and value using the 236 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com